| PACKAGING TYPE: | 10x10 Alu-alu (10 Strips In 1 Box) |
| COMPOSITION: | Vildagliptin (100mg)+dapagliflozin (10mg) |
| FORMULATION: | Tablet |
| Description: | VIDASAFE D 100/10 Tablet is a combination oral antidiabetic medication containing Vildagliptin 100mg and Dapagliflozin 10mg. It is prescribed for type 2 diabetes mellitus to provide enhanced glycemic control. Vildagliptin (DPP-4 inhibitor) increases incretin hormones, enhancing insulin secretion and reducing glucagon release. Dapagliflozin (SGLT2 inhibitor) promotes glucose excretion through the urine, lowering blood sugar levels. This dual-mechanism therapy offers effective blood sugar management, potential weight benefits, and a reduced risk of hypoglycemia compared to some other oral antidiabetics. |
| Side Effects: | Common side effects: Urinary tract infections Increased urination Headache or dizziness Nausea or mild stomach discomfort Serious (rare) side effects: Severe allergic reactions Pancreatitis (abdominal pain, nausea, vomiting) Kidney function abnormalities Low blood pressure or dehydration |
| How to Use: | Take the tablet as prescribed by your doctor Typically administered once daily, with or without food Swallow the tablet whole with water Regular blood sugar monitoring is recommended |
| Precaution: | Use cautiously in patients with kidney or liver issues Maintain adequate hydration while on therapy Inform your doctor of all other medications and medical conditions Not recommended during pregnancy or breastfeeding unless prescribed Monitor blood sugar and kidney function regularly |
| Product Benefits: | Strong dual-action blood sugar control Enhances insulin secretion and reduces glucagon (Vildagliptin) Promotes urinary glucose excretion (Dapagliflozin) Suitable for patients inadequately controlled on monotherapy May support weight management and red |
Frequently Asked Questions
It is used to improve blood sugar control in type 2 diabetes by combining Vildagliptin and Dapagliflozin.
Vildagliptin increases insulin and lowers glucagon, while Dapagliflozin promotes urinary glucose excretion for dual glucose-lowering effect.
Yes, Dapagliflozin may contribute to mild weight reduction along with better glycemic control.















